Research
Hormonal
The N363S polymorphism is associated with increased glucocorticoid sensitivity, higher BMI, and increased insulin response to dexamethasone, though associations with BMI are controversial across different populations.
If you carry the N363S variant, your body is more sensitive to cortisol, which may contribute to higher BMI and insulin response. Monitor your stress levels and metabolic health, as your biology may predispose you to weight gain and insulin resistance compared to non-carriers.
ModerateQualifiesMEDIUM confidence
The N363S polymorphism has been associated with increased sensitivity to GCs, increased insulin response to DEX, a tendency towards lower bone mineral density, and increased body mass index (BMI). However, other reports found no associations with BMI.
Why this rating
Mixed results across studies regarding BMI, though GC sensitivity is consistently higher.
Source
Polymorphisms in the Glucocorticoid Receptor Gene and Their Associations with Metabolic Parameters and Body Composition
Elisabeth F. C. van Rossum · Recent Progress in Hormone Research · 2004
DOI 10.1210/rp.59.1.333
narrative_reviewCited 379×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The ER22/23EK polymorphism in the glucocorticoid receptor gene confers relative resistance to glucocorticoids, resulting in a healthier metabolic profile characterized by lower fasting insulin, increased insulin sensitivity, and lower cholesterol levels.Good
- The ER22/23EK polymorphism is associated with increased lean body mass and muscle strength in young adult males, and reduced abdominal fat measures in young adult females, due to relative glucocorticoid resistance.Good
- The ER22/23EK polymorphism is associated with a lower risk of dementia, fewer white matter lesions, and significantly better survival rates in the elderly.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →